Jeremy Hayden Sells 9,385 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy Hayden sold 9,385 shares of Sight Sciences stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $73,390.70. Following the transaction, the insider directly owned 247,205 shares in the company, valued at approximately $1,933,143.10. This represents a 3.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sight Sciences Stock Performance

SGHT stock opened at $7.44 on Thursday. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The firm has a market cap of $393.35 million, a PE ratio of -8.27 and a beta of 2.42. The business has a 50 day moving average of $7.57 and a 200-day moving average of $5.15. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $9.24.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The business had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SGHT. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. UBS Group increased their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Lake Street Capital lifted their price target on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 21st. Piper Sandler set a $9.00 price objective on Sight Sciences in a research note on Monday. Finally, Citigroup increased their price objective on Sight Sciences from $5.50 to $9.10 and gave the company a “neutral” rating in a report on Thursday, December 11th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.30.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. KCK LTD. purchased a new position in Sight Sciences during the second quarter valued at approximately $18,069,000. Americana Partners LLC purchased a new stake in Sight Sciences in the 2nd quarter worth approximately $3,568,000. Acadian Asset Management LLC boosted its holdings in Sight Sciences by 127.7% in the 1st quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock valued at $1,033,000 after purchasing an additional 242,559 shares during the period. Vanguard Group Inc. boosted its holdings in Sight Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock valued at $6,559,000 after purchasing an additional 102,609 shares during the period. Finally, B Group Inc. grew its position in shares of Sight Sciences by 11.6% during the 2nd quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after purchasing an additional 96,400 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Sight Sciences News Summary

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight, which can attract buying from institutions and retail investors and support near-term positive sentiment. Read More.
• Neutral Sentiment: Key insiders still hold large stakes (CEO Paul Badawi ~5.9M shares; CTO David Badawi ~1.9M shares), which suggests ongoing long-term alignment despite recent sales and may limit fears of full insider exit. Read More.
• Negative Sentiment: Multiple executives (CEO, CTO, CFO, EVP and other insiders) disclosed sales between Jan. 2–6 totaling roughly $0.48M in proceeds. The clustered timing and size of the trades — even though each is a small percentage of holdings — can create short-term downward pressure or signal near‑term liquidity needs. Read More.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.